Cargando…

25‐Hydroxycholesterol protects against acute lung injury via targeting MD‐2

Acute lung injury (ALI) is mainly caused by uncontrolled inflammatory response, and it remains without effective therapeutic options. 25‐hydroxycholesterol (25HC) has been reported to be a potent regulator of inflammation. The aim of this study was to investigate the effects of 25HC on lipopolysacch...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouyang, Wei, Zhou, Hui, Liu, Chao, Wang, Shiwei, Han, Yu, Xia, Jingyan, Xu, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201372/
https://www.ncbi.nlm.nih.gov/pubmed/30091835
http://dx.doi.org/10.1111/jcmm.13820
_version_ 1783365484757909504
author Ouyang, Wei
Zhou, Hui
Liu, Chao
Wang, Shiwei
Han, Yu
Xia, Jingyan
Xu, Feng
author_facet Ouyang, Wei
Zhou, Hui
Liu, Chao
Wang, Shiwei
Han, Yu
Xia, Jingyan
Xu, Feng
author_sort Ouyang, Wei
collection PubMed
description Acute lung injury (ALI) is mainly caused by uncontrolled inflammatory response, and it remains without effective therapeutic options. 25‐hydroxycholesterol (25HC) has been reported to be a potent regulator of inflammation. The aim of this study was to investigate the effects of 25HC on lipopolysaccharide (LPS)‐induced ALI. C57BL/6 mice were pretreated with 25HC intraperitoneally before intratracheal exposure to LPS. Our results showed that 25HC pretreatment improved survival rate, attenuated the pathological changes of the lung and decreased the release of inflammatory cytokines in mice. Consistently, 25HC reduced expression of Toll‐like receptor (TLR4)‐mediated inflammatory cytokines in vitro. These effects of 25HC were obtained by preventing LPS binding to TLR4 via interaction with myeloid differentiation protein 2 (MD‐2). Crystal structure analysis suggested that 25HC could bind MD‐2 with high affinity into its hydrophobic pocket. Furthermore, LPS‐induced activation of Akt/NF‐κB pathway was partially down‐regulated by 25HC pretreatment. In summary, this study demonstrates that 25HC could inhibit the overwhelming inflammatory response through MD‐2 interaction, which suppresses Akt/NF‐κB signalling pathway. These findings suggest 25HC may be a promising candidate for ALI prevention.
format Online
Article
Text
id pubmed-6201372
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62013722018-11-01 25‐Hydroxycholesterol protects against acute lung injury via targeting MD‐2 Ouyang, Wei Zhou, Hui Liu, Chao Wang, Shiwei Han, Yu Xia, Jingyan Xu, Feng J Cell Mol Med Original Articles Acute lung injury (ALI) is mainly caused by uncontrolled inflammatory response, and it remains without effective therapeutic options. 25‐hydroxycholesterol (25HC) has been reported to be a potent regulator of inflammation. The aim of this study was to investigate the effects of 25HC on lipopolysaccharide (LPS)‐induced ALI. C57BL/6 mice were pretreated with 25HC intraperitoneally before intratracheal exposure to LPS. Our results showed that 25HC pretreatment improved survival rate, attenuated the pathological changes of the lung and decreased the release of inflammatory cytokines in mice. Consistently, 25HC reduced expression of Toll‐like receptor (TLR4)‐mediated inflammatory cytokines in vitro. These effects of 25HC were obtained by preventing LPS binding to TLR4 via interaction with myeloid differentiation protein 2 (MD‐2). Crystal structure analysis suggested that 25HC could bind MD‐2 with high affinity into its hydrophobic pocket. Furthermore, LPS‐induced activation of Akt/NF‐κB pathway was partially down‐regulated by 25HC pretreatment. In summary, this study demonstrates that 25HC could inhibit the overwhelming inflammatory response through MD‐2 interaction, which suppresses Akt/NF‐κB signalling pathway. These findings suggest 25HC may be a promising candidate for ALI prevention. John Wiley and Sons Inc. 2018-08-09 2018-11 /pmc/articles/PMC6201372/ /pubmed/30091835 http://dx.doi.org/10.1111/jcmm.13820 Text en © 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Ouyang, Wei
Zhou, Hui
Liu, Chao
Wang, Shiwei
Han, Yu
Xia, Jingyan
Xu, Feng
25‐Hydroxycholesterol protects against acute lung injury via targeting MD‐2
title 25‐Hydroxycholesterol protects against acute lung injury via targeting MD‐2
title_full 25‐Hydroxycholesterol protects against acute lung injury via targeting MD‐2
title_fullStr 25‐Hydroxycholesterol protects against acute lung injury via targeting MD‐2
title_full_unstemmed 25‐Hydroxycholesterol protects against acute lung injury via targeting MD‐2
title_short 25‐Hydroxycholesterol protects against acute lung injury via targeting MD‐2
title_sort 25‐hydroxycholesterol protects against acute lung injury via targeting md‐2
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201372/
https://www.ncbi.nlm.nih.gov/pubmed/30091835
http://dx.doi.org/10.1111/jcmm.13820
work_keys_str_mv AT ouyangwei 25hydroxycholesterolprotectsagainstacutelunginjuryviatargetingmd2
AT zhouhui 25hydroxycholesterolprotectsagainstacutelunginjuryviatargetingmd2
AT liuchao 25hydroxycholesterolprotectsagainstacutelunginjuryviatargetingmd2
AT wangshiwei 25hydroxycholesterolprotectsagainstacutelunginjuryviatargetingmd2
AT hanyu 25hydroxycholesterolprotectsagainstacutelunginjuryviatargetingmd2
AT xiajingyan 25hydroxycholesterolprotectsagainstacutelunginjuryviatargetingmd2
AT xufeng 25hydroxycholesterolprotectsagainstacutelunginjuryviatargetingmd2